Ernexa Therapeutics Inc. Business Acquisition, Pro Forma Earnings Per Share, Diluted
Ernexa Therapeutics Inc. (ERNA) reported Business Acquisition, Pro Forma Earnings Per Share, Diluted of -$2.83 per share for the 12-month period ending 2021-12-31, per its 10-K/A filed 2022-07-01.
Discontinued › Income Statement › Earnings Per Share
us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted · last filed 2022-07-01
- Ernexa Therapeutics Inc. business acquisition, pro forma earnings per share, diluted for the quarter ending 2021-06-30 was -$0.79.
- Ernexa Therapeutics Inc. business acquisition, pro forma earnings per share, diluted for the quarter ending 2021-03-31 was -$0.64.
- Ernexa Therapeutics Inc. business acquisition, pro forma earnings per share, diluted for the quarter ending 2020-06-30 was -$0.17.
- Ernexa Therapeutics Inc. business acquisition, pro forma earnings per share, diluted for the quarter ending 2020-03-31 was -$0.06.
- Ernexa Therapeutics Inc. business acquisition, pro forma earnings per share, diluted for fiscal 2021 was -$2.83.
- Ernexa Therapeutics Inc. business acquisition, pro forma earnings per share, diluted for fiscal 2020 was -$0.42.
| Period end | Business Acquisition, Pro Forma Earnings Per Share, Diluted 3 month | Business Acquisition, Pro Forma Earnings Per Share, Diluted 9 month | Business Acquisition, Pro Forma Earnings Per Share, Diluted 12 month | Business Acquisition, Pro Forma Earnings Per Share, Diluted 12 month as first filed |
|---|---|---|---|---|
| 2021-12-31 | -$2.83 10-K/A · filed 2022-07-01 | -$2.82 10-K · filed 2022-04-15 | ||
| 2021-09-30 | -$2.82 10-Q · filed 2021-11-12 | |||
| 2021-06-30 | -$0.79 10-Q · filed 2021-08-13 | |||
| 2021-03-31 | -$0.64 10-Q · filed 2021-05-17 | |||
| 2020-12-31 | -$0.42 10-K/A · filed 2022-07-01 | -$1.51 10-K · filed 2022-04-15 | ||
| 2020-09-30 | -$0.29 10-Q · filed 2021-11-12 | |||
| 2020-06-30 | -$0.17 10-Q · filed 2021-08-13 | |||
| 2020-03-31 | -$0.06 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |